|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 帕博利珠单抗治疗伴脑转移NSCLC患者的一项非随机、开放Ⅱ期试验的长期随访结果和生物标志物分析显示文摘背景与目的我们开展了一项帕博利珠单抗用于伴未治疗脑转移的非小细胞肺癌(non-small cell lung cancer,NSCLC)或黑色素瘤患者的疗效和安全性的II期试验,旨在评估程序性死亡受体1(programmed cell death 1,PD-1)抑制剂在中枢神经系统(central nervous system,CNS)中的疗效。中期结果已发表,现报道对NSCLC队列的更新分析结果。方法这是一项开放性、单中心、II期试验。纳入标准:年龄≥18岁,诊断为晚期NSCLC并伴有≥1个5 mm-20 mm脑转移病灶,既往从未治疗或之前放疗后进展,无神经系统症状,不需要激素治疗且美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)<2分。患者每2周接受一次帕博利珠单抗(10 mg/kg)治疗。队列1为程序性死亡配体1(programmed cell death ligand 1,PD-L1)≥1%的患者,队列2为PD-L1<1%或未评估的患者。主要终点是脑转移患者缓解比例。所有经治患者均纳入疗效与安全性终点的分析。该研究已结束入组,并于Clinicaltrials.gov登记注册,注册号为NCT02085070。结果2014年3月31日-2018年5月21日,共42例患者接受治疗。中位随访时间为8.3个月(IQR:4.5个月-26.2个月)。队列1的37例患者中11例有脑转移缓解[29.7%(95%CI:15.9%-47.0%)]。队列2未观察到缓解。治疗相关的3级-4级不良事件(adverse events,AEs)包括2例肺炎、1例全身症状、1例结肠炎、1例肾上腺皮质功能不全、1例高血糖症和1例低钾血症。6例(14%)患者发生了治疗相关的严重不良事件,包括肺炎、急性肾损伤、低钾血症和肾上腺皮质功能不全。没有观察到治疗相关死亡病例。结论帕博利珠单抗治疗PD-L1≥1%的NSCLC伴脑转移患者有效,且对所有纳入的未经治疗的脑转移患者安全。需要进一步探索免疫治疗用于NSCLC合并CNS转移。 | Sarah B GOLDBERG Kurt A SCHALPER Scott N GETTINGER Amit MAHAJAN Roy S HERBST Anne C CHANG Rogerio LILENBAUM Frederick H WILSON Sacit Bulent OMAY James B YU Lucia JILAVEANU Thuy TRAN Kira PAVLIK Elin ROWEN Heather GERRSH Annette KOMLO Richa GUPTA Hailey WYATT Matthew RIBEIRO Yuval KLUGER Geyu ZHOU Wei WEI Veronica L CHANG Harriet M KLUGER 董晓荣(翻译/校对) | 2021 | 中国肺癌杂志2021，24，9： | 34 |
| 2 | 非小细胞肺癌的个体化治疗进展显示文摘肺癌是全球癌症相关死亡的最常见原因.在过去20年中,分子靶向治疗和免疫治疗显著改善了非小细胞肺癌(non-small-cell lung cancer,NSCLC)患者的预后.然而,绝大多数的晚期NSCLC会对目前治疗产生耐药,最终出现疾病进展.基于此,本综述就近年来出现的一些突破性NSCLC治疗方法,尤其是免疫治疗和靶向治疗展开讨论.同时强调了目前我们对耐药机制的理解以及将基因组分析纳入临床研究以进一步理解机制的重要性.我们认为新辅助和联合的维持治疗在未来有可能使早期阶段疾病得到治愈.合理的联合治疗未来发展所面临的主要挑战是如何通过可靠的预测性生物标志物将患者清晰分层.本文阐述了我们对未来十年可能影响NSCLC治疗策略的临床研究领域的观点. | Meina WANG Roy S HERBST Chris BOSHOFF 杨雪(译校) 赵军(译校) | 2022 | 中国肺癌杂志2022，25，3： | 5 |
| 3 | Review of epidermal growth factor receptor biology显示文摘 | Roy S Herbst | 2004 | International Journal of Radiation Oncology, Biology, Physics2004，，2： | 3 |
| 4 | Allelic loss at the nourofibromatosis type I(NF-1) gene locus is frequent in desmoplastic neurotropic melanoma显示文摘 | Gutzmer R Herbst RA Mommert S | 2000 | Hum tenet2000，107，4： | 1 |
| 5 | Endostatin improves radio- response and blocks tumor revascularization after radiation therapy for A431 xenografts in mice显示文摘 | Itasaka S Komaki R Herbst R S | 2007 | International Journal of Radiation On- cology Biology Physics2007，67，3： | 1 |
| 6 | Oxidation of AISI 304 and AISI 439 stainless steels显示文摘 | A.M. Huntz A. Reckmann C. Haut C. Sévérac M. Herbst F.C.T. Resende A.C.S. Sabioni | 2006 | Materials Science & Engineering A2006，，1： | 1 |
| 7 | Cellular localization of type Ⅱ,Ⅲand Ⅳ procollagen gene transcripts in normal and flbrotic human liver显示文摘 | Herbst H Schuppan D | 1990 | Am J Pathol1990，137，1： | 1 |
| 8 | Evaluation of am- monium molybdophosphate polyacrylonitrile as a cesium se- lective sorbent for the removal of I37Cs from acidic nuclear waste solutions显示文摘 | Tranter T Herbst R S Todd T A | 2002 | Adv Environ Res2002，6，： | 1 |
| 9 | Angiogenesis inhibitors in lung cancer显示文摘 | Herbst R S | 2002 | Curr Oncol Rep2002，4，4： | 1 |
| 10 | Diphenylcy-clopropenone treatment of alopecia areata induces apoptosis of Perifollicular lym-phocytes显示文摘 | Herbst V Kissling S Wenzel E | 2006 | European Journal of Dermatology2006，16，5： | 1 |
| 11 | Review of epidermal growth factor receptor biology 显示文摘 | Herbst R S | 2004 | Int J Radiat Oncol Biol Phys2004，59，2： | 1 |
| 12 | Tumor Cavitation in Stage I Non Small Cell Lung Cancer: Epidermal Growth Factor Receptor Expression and Prediction of Poor Outcome显示文摘 | Amir Onn Du I1wan Choe Roy S Herbst | 2005 | Radiology2005，237，： | 1 |
| 13 | A phase I/II A trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer 显示文摘 | Herbst R S Hammond L A Carbone D P etal | 2003 | Clin Cancer Res2003，9，11： | 1 |
| 14 | Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation显示文摘 | Yano S Herbst RS Shinohara H | 2000 | Clin Cancer Res2000，6，： | 1 |
| 15 | Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well- tolerated and has activity in non-small- cell lung cancer and other solid tumors:results of a phase I trial 显示文摘 | Herbst R S Maddox A M Rothenberg M L | 2002 | J Clin Oncol2002，20，18： | 1 |
| 16 | Endostatin improves radioresponse and blocks tumor revascuhrization after radiation therapy for A431 xenografis in mice显示文摘 | Itssaka S Komaki R Herbst R S | | 0，，03： | 1 |
| 17 | Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice 显示文摘 | Itasaka S Komaki R Herbst RS | 2007 | Int J Radiat Oncol Biol Phys2007，67，3： | 1 |
| 18 | Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC) : a double-blind, randomised, phase 3 trial 显示文摘 | Herbst R S Sun Y Eberhardt W E | 2010 | Lancet Oncol2010，11，7： | 1 |
| 19 | Postoperative course and long term follow up after colectomy for slow transit constipation-is surgery an appropriate approach显示文摘 | Riss S Herbst F Birsan T | | 0，，3： | 1 |
| 20 | Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non small cell lung cancer treated with chemo- therapy alone and in combination with erlotinib 显示文摘 | Eberhard D A Johnson B E Amler L C Goddard A D Heldens S L Herbst R S | 2005 | J Clin On- col2005，23，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员